コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 cluding AIDS-associated Kaposi's sarcoma and multicentric Castleman's disease.
2 rcoma, primary effusion B-cell lymphoma, and multicentric Castleman's disease.
3 ch accounts for at least 33% of all cases of multicentric Castleman's disease.
4 ntric Castleman's disease from 1923 cases of multicentric Castleman's disease.
5 posi sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
6 , treatments for, and outcomes of idiopathic multicentric Castleman's disease.
7 idiopathic; such cases are called idiopathic multicentric Castleman's disease.
8 a (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease.
9 arcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease.
10 nked with KS, primary effusion lymphoma, and multicentric Castleman's disease.
11 interleukin 6-in HIV-negative patients with multicentric Castleman's disease.
12 rus-8-seronegative patients with symptomatic multicentric Castleman's disease.
13 arcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease.
14 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
15 ses, including primary effusion lymphoma and multicentric Castleman's disease.
16 include primary effusion lymphoma (PEL) and multicentric Castleman's disease.
17 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
18 arcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease.
19 athogenesis of primary effusion lymphoma and multicentric Castleman's disease.
20 ies, including primary effusion lymphoma and multicentric Castleman's disease.
21 i's sarcoma, primary effusion lymphomas, and multicentric Castleman's disease.
22 sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's disease.
23 primary effusion lymphoma, and some forms of multicentric Castleman's disease.
24 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
25 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
26 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
27 phoma (PEL) and the plasmablastic variant of multicentric Castleman's disease.
28 a (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease.
29 primary effusion lymphoma, and plasmablastic multicentric Castleman's disease.
30 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
31 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
32 as well as of primary effusion lymphoma and multicentric Castleman's disease.
33 gnancies, KS, primary effusion lymphoma, and multicentric Castleman's disease.
34 usion lymphoma and the plasmablastic form of multicentric Castleman's disease.
35 imary effusion lymphoma and in some cases of multicentric Castleman's disease.
36 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
37 as well as in primary effusion lymphoma and multicentric Castleman's disease.
38 tve disorders, primary effusion lymphoma and multicentric Castleman's disease.
39 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
40 of KS, primary effusion lymphoma (PEL), and multicentric Castleman's disease.
41 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
42 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
43 sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's disease.
44 primary effusion lymphoma and some cases of multicentric Castleman's disease.
45 related non-Hodgkin's lymphomas (NHL) and in multicentric Castleman's disease.
46 in body cavity-based lymphomas (BCBL) and in multicentric Castleman's disease.
47 ody cavity-based lymphomas, and AIDS-related multicentric Castleman's disease.
48 ted lymphomas, and from a high proportion of multicentric Castleman's disease.
49 nked with KS, primary effusion lymphoma, and multicentric Castleman's disease.
50 resemble KSHV-associated diseases including multicentric Castleman's disease and non-Hodgkin's lymph
52 to two B cell lymphoproliferative disorders, multicentric Castleman's disease and primary effusion ly
53 ive care alone for patients with symptomatic multicentric Castleman's disease and well tolerated with
54 be the etiologic agent of Kaposi's sarcoma, multicentric Castleman's disease, and AIDS-associated pr
56 r Kaposi sarcoma, primary effusion lymphoma, multicentric Castleman's disease, and KSHV inflammatory
57 and the causative agent of Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion l
58 posi sarcoma (KS), the plasmablastic form of multicentric Castleman's disease, and primary effusion l
59 (KSHV) is the etiologic agent for KS tumors, multicentric Castleman's disease, and primary effusion l
60 us (KSHV) is found in Kaposi's sarcoma (KS), multicentric Castleman's disease, and primary effusion l
61 posi sarcoma (KS), the plasmablastic form of multicentric Castleman's disease, and primary effusion l
62 ciated with primary effusion lymphoma (PEL), multicentric Castleman's disease, and two inflammatory d
63 with the development of Kaposi's sarcoma and multicentric Castleman's disease, as well as a rare form
64 ssociated with primary effusion lymphoma and multicentric Castleman's disease, as well as its namesak
65 induced hyperplasia to monoclonal neoplasia: multicentric Castleman's disease (CD), Kaposi's sarcoma
67 tified 626 (33%) patients with HHV8-negative multicentric Castleman's disease from 1923 cases of mult
68 24 (19%) of 128 patients with idiopathic multicentric Castleman's disease had a diagnosis of a se
70 si's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease; in all of these diseas
75 readily detected in KSHV-positive cells from multicentric Castleman's disease (MCD) and Kaposi's sarc
76 rimary effusion lymphoma (PEL) and a form of multicentric Castleman's disease (MCD) are both caused b
78 effusion lymphoma (PEL) cell lines, PEL and multicentric Castleman's disease (MCD) tumors, Kaposi's
79 a (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), all of which are
80 us casually linked to Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effu
81 alignancies including Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effu
82 ic agent of primary effusion lymphoma (PEL), multicentric Castleman's disease (MCD), and the inflamma
83 arcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), in addition to a
84 f HHV-8-associated Kaposi's sarcoma, PEL and multicentric Castleman's disease (MCD), in addition to p
85 man's disease (UCD) or the dominant focus in multicentric Castleman's disease (MCD), nature of the su
86 a (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), three diseases t
99 iological agent of three human malignancies: multicentric Castleman's disease, primary effusion lymph
100 of centralised information about idiopathic multicentric Castleman's disease represents a major chal
101 e cells infected with human herpesvirus-8 in multicentric Castleman's disease support lytic replicati
102 s been associated with both malignancies and multicentric Castleman's disease; the latter is a rare a
103 arcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease through autocrine or pa
105 egated data for 127 patients with idiopathic multicentric Castleman's disease were presented from cli
106 tures, treatment, and outcomes of idiopathic multicentric Castleman's disease, which accounts for at